In this issue of Cancer Cell, Bolli et al. leverage a newly developed neutrophil analysis framework to identify CCL3 as a conserved marker for tumor-associated neutrophils (TANs) across human and murine cancers. Using complementary genetic manipulation strategies, they demonstrate that neutrophil-derived CCL3 supports pro-tumor TAN survival within hypoxic tumor niches.
Cancer Cell published a clinical update in Oncology on 12 Feb 2026.
The item focuses on A conserved, terminal, pro-tumor neutrophil population.
Review the original article for the full source wording and details.